Advanced Cancer Treatment Trials

In most cases, the immune system detects and destroys cells that could become cancerous every day. For cancer to ravage the body, it needs to evade the immune system by shutting off its response. SIRPant Immunotherapeutics is seeking to address cancer by activating and modifying a patient’s own macrophages to awaken the immune system to cancer. The activated macrophages are able to recognize and directly attack cancer cells throughout the body and stimulate other parts of the immune system to sustain a prolonged attack. We spoke to Robert Towarnicki, CEO of SIRPant, about the company’s immunotherapies, the advantages they offer over other approaches, and why its platform can be applied to other diseases involving immune dysfunction beyond cancer.